-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexicon Pharma Presents Post-Hoc Analysis Of Clinical Study Data Showing Reduction In Hypoglycemic Events When Sotagliflozin Was Added To Optimized Insulin Therapy For People With T1D, At Scientific Sessions Of ADA

Benzinga·06/23/2025 12:30:46
Listen to the news

Oral presentation highlighted the post-hoc analysis during the "Interventions to Prevent Hypoglycemia: Bench to Bedside" session

Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL

THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that a post-hoc analysis of clinical study data showing a reduction in hypoglycemic events when sotagliflozin was added to optimized insulin therapy for people with type 1 diabetes (T1D) was presented yesterday during the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois.